Bone marrow-derived mesenchymal stem cells for treatment of heart failure: Is it all paracrine actions and immunomodulation?

Journal of Cardiovascular Medicine

Volumn 9, Issue 2, 2008, Pages 122-128

  Mishra, Pankaj Kumar ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Heart failure; Immunomodulation; Mesenchymal stem cells; Paracrine actions

Indexed keywords

BONE MARROW; CELL THERAPY; EMBRYONIC STEM CELL; HEART FAILURE; HEART VENTRICLE FUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; MESENCHYMAL STEM CELL; MUSCLE REGENERATION; NONHUMAN; PARACRINE SIGNALING; REVIEW; T LYMPHOCYTE;

ANIMALS; BONE MARROW CELLS; CELL PROLIFERATION; HEART; HEART FAILURE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; PARACRINE COMMUNICATION; REGENERATION; T-LYMPHOCYTES;

EID: 38149132490     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32820588f0     Document Type: Review

References (78)

1. Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001; 107:1395-1402.
2. Pfeffer MA. Left ventricular remodeling after acute myocardial infarction. Annu Rev Med 1995; 46:455-466.
3. Saraste A, Pulkki K, Kallajoki M, Heikkila P, Laine P, Mattila S, et al. Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur J Clin Invest 1999; 29:380-386.
4. Khoynezhad A, Jalali Z, Tortolani AJ. Apoptosis: pathophysiology and therapeutic implications for the cardiac surgeon. Ann Thorac Surg 2004; 78:1109-1118.
5. Foo RS, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest 2005; 115:565-571.
6. Takemura G, Fujiwara H. Role of apoptosis in remodeling after myocardial infarction. Pharmacol Ther 2004; 104:1-16.
7. Li RK, Yau TM, Sakai T, Mickle DA, Weisel RD. Cell therapy to repair broken hearts. Can J Cardiol 1998; 14:735-744.
8. Nishida M, Li TS, Hirata K, Yano M, Matsuzaki M, Hamano K. Improvement of cardiac function by bone marrow cell implantation in a rat hypoperfusion heart model. Ann Thorac Surg 2003; 75:768-774.
9. Xu X, Xu Z, Xu Y, Cui G. Effects of mesenchymal stem cell transplantation on extracellular matrix after myocardial infarction in rats. Coron Artery Dis 2005; 16:245-255.
10. Orlic D, Hill JM, Arai AE. Stem cells for myocardial regeneration. Circ Res 2002; 91:1092-1102.
11. Jaquet K, Krause KT, Denschel J, Faessler P, Nauerz M, Geidel S, et al. Reduction of myocardial scar size after implantation of mesenchymal stem cells in rats: what is the mechanism? Stem Cells Dev 2005; 14:299-309.
12. Menasche P. Cellular transplantation: hurdles remaining before widespread clinical use. Curr Opin Cardiol 2004; 19:154-161.
13. Chachques JC, Acar C, Herreros J, Trainini JC, Prosper F, D'Attellis N, et al. Cellular cardiomyoplasty: clinical application. Ann Thorac Surg 2004; 77:1121-1130.
14. Siepe M, Heilmann, von Samson P, Menasche P, Beyersdorf F. Stem cell research and cell transplantation for myocardial regeneration. Eur J Cardiothorac Surg 2005; 28:318-324.
15. Pagani FD, DerSimonian H, Zawadzka A, Wetzel K, Edge AS, Jacoby DB, et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol 2003; 41:879-888.
16. Li RK, Jia ZQ, Weisel RD, Mickle DA, Zhang J, Mohabeer MK, et al. Cardiomyocyte transplantation improves heart function. Ann Thorac Surg 1996; 62:654-660.
17. Sakai T, Li RK, Weisel RD, Mickle DA, Kim EJ, Tomita S, et al. Autologous heart cell transplantation improves cardiac function after myocardial injury. Ann Thorac Surg 1999; 68:2074-2081.
18. Gronthos S, Simmons PJ. The biology and application of human bone marrow stromal cell precursors. J Hematother 1996; 5:15-23.
19. Friedenstein AJ, Petrokova KV. Osteogenesis in transplants of bone marrow cells. Journal of Embryological Experimental Morphology 1966; 16:381-390.
20. Haynesworth SE, Goshima J, Goldberg VM, Caplan AI. Characterization of cells with osteogenic potential from human marrow. Bone 1992; 13:81-88.
21. Barry FP. Biology and clinical applications of mesenchymal stem cells. Birth Defects Res C Embryo Today 2003; 69:250-256.
22. Plumas J, Chaperot L, Richard MJ, Molens JP, Bensa JC, Favrot MC. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005; 19:1597-1604.
23. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-147.
24. Jorgensen C, Djouad F, Apparailly F, Noel D. Engineering mesenchymal stem cells for immunotherapy. Gene Ther 2003; 10:928-931.
25. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004; 36:568-584.
26. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11:321-334.
27. Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy 2005; 7:36-45.
28. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003; 5:485-489.
29. El-Badri NS, Maheshwari A, Sanberg PR. Mesenchymal stem cells in autoimmune disease. Stem Cells Dev 2004; 13:463-472.
30. Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005; 2:8.
31. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410:701-705.
32. Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P. Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann N Y Acad Sci 2001; 938:221-229.
33. Sakai T, Li RK, Weisel RD, Mickle DA, Jia ZQ, Tomita S, et al. Fetal cell transplantation: a comparison of three cell types. J Thorac Cardiovasc Surg 1999; 118:715-724.
34. Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003; 361:45-46.
35. Galinanes M, Loubani M, Davies J, Chin D, Pasi J, Bell PR. Autotransplantation of unmanipulated bone marrow into scarred myocardium is safe and enhances cardiac function in humans. Cell Transplant 2004; 13:7-13.
36. Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004; 44:1690-1699.
37. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003; 9:702-712.
38. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 2001; 98:10344-10349.
39. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430-436.
40. Edelberg JM, Tang L, Hattori K, Lyden D, Rafii S. Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. Circ Res 2002; 90:E89-E93.
41. Yeh ET, Zhang S, Wu HD, Korbling M, Willerson JT, Estrov Z. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 2003; 108:2070-2073.
42. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428:664-668.
43. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004; 428:668-673.
44. Shake JG, Gruber PJ, Baumgartner WA, Senechal G, Meyers J, Redmond JM, et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 2002; 73:1919-1925.
45. Tomita S, Li RK, Weisel RD, Mickle DA, Kim EJ, Sakai T, et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999; 100 (Suppl):II247-II256.
46. Wang JS, Shum-Tim D, Chedrawy E, Chiu RC. The coronary delivery of marrow stromal cells for myocardial regeneration: pathophysiologic and therapeutic implications. J Thorac Cardiovasc Surg 2001; 122:699-705.
47. Tang YL, Zhao Q, Qin X, Shen L, Cheng L, Ge J, et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg 2005; 80:229-237.
48. Tang YL, Qian K, Zhang YC, Shen L, Phillips MI. Mobilizing of haematopoietic stem cells to ischemic myocardium by plasmid mediated stromal-cell-derived factor-1alpha (SDF-1alpha) treatment. Regul Pept 2005; 125:1-8.
49. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001; 104:1046-1052.
50. Besse A, Trimoreau F, Praloran V, Denizot Y. Effect of cytokines and growth factors on the macrophage colony-stimulating factor secretion by human bone marrow stromal cells. Cytokine 2000; 12:522-525.
51. Bick-Forrester J, Lee MS, Makkar RR, Forrester JS. Partial restoration of myocardial function and perfusion by cell therapy following myocardial infarction. Curr Opin Cardiol 2004; 19:631-637.
52. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57:11-20.
53. Kofidis T, deBruin JL, Tanaka M, Zwierzchoniewska M, Weissman I, Fedoseyeva E, et al. They are not stealthy in the heart: embryonic stem cells trigger cell infiltration, humoral and T-lymphocyte-based host immune response. Eur J Cardiothorac Surg 2005; 28:461-466.
54. McIntosh K, Bartholomew A. Stromal cell modulation of the immune system. A potential role for mesenchymal stem cells. Graft 2000; 3:324-328.
55. Majumdar MK, Keane-Moore M, Buyaner D, Hardy WB, Moorman MA, McIntosh KR, et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 2003; 10:228-241.
56. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99:3838-3843.
57. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75:389-397.
58. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102:3837-3844.
59. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30:42-48.
60. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305:33-41.
61. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76:1208-1213.
62. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003; 171:3426-3434.
63. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101:3722-3729.
64. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363:1439-1441.
65. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815-1822.
66. Van den Eynde B, Gaugler B, van der Bruggen P, Coulie P, Brichard V, Boon T. Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines. Biochem Soc Trans 1995; 23:681-686.
67. Strand S, Galle PR. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today 1998; 4:63-68.
68. Mitra R, Singh S, Khar A. Antitumour immune responses. Expert Rev Mol Med 2003; 2003:1-22.
69. Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005; 129:118-129.
70. Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, Haynesworth SE, et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004; 33:597-604.
71. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103:4619-4621.
72. Zhang W, Ge W, Li C, You S, Liao L, Han Q, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004; 13:263-271.
73. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105:4120-4126.
74. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005; 12:47-57.
75. Bordignon C, Carlo-Stella C, Colombo MP, De Vincentiis A, Lanata L, Lemoli RM, et al. Cell therapy: achievements and perspectives. Haematologica 1999; 84:1110-1149.
76. Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 2006; 24:462-471.
77. Kadri T, Lataillade JJ, Doucet C, Marie A, Ernou I, Bourin P, et al. Proteomic study of Galectin-1 expression in human mesenchymal stem cells. Stem Cells Dev 2005; 14:204-212.
78. Frassoni F, Labopin M, Bacigalupo A, Gluckman E, Rocha V, Bruno B, et al. Expanded mesenchymal stem cells (MSC), co-infused with HLA identical hematopoietic stem cell transplants, reduce acute and chronic graft versus host disease: a matched pair analysis [abstract]. Bone Marrow Transplant 2002; 29 (Suppl 2):S2.